We reviewed the role of COX-2 independent targets of celecoxib and related compounds in cancer prevention and treatment. Direct non-COX-2 targets of celecoxib might be protein-dependent kinase 1 (PDK-1),Ca+ ATPase and carbonic anhydrase (CA), and so on; all of which are inhibited by celecoxib and are the main components in various pathways. Inhibition of these proteins leads to the induction of apoptnsis, the inhibition of cell cycle progression, angiogenesis, and metastasis, which are the main mechanisms by which celecoxib exerts its anticarcinogenic activity.

Objective To investigate the clinical significance of heat shock protein 27(HSP-27) and glypican-3(GPC-3) in diag-nosing primary hepatic cancer (PHC) and the clinicopathologic characteristics by detecting their expression in PHC .Methods Im-munohistochemistry was used to detect the expression of HSP-27 and GPC-3 in 32 cases of PHC tissue ,30 cases of live cirrhosis tissue ,25 cases of benign liver occupying tissue and 31 cases of hepatitis tissue .The relationship between their expression and the clinicopathologic features of PHC was analyzed .Results HSP-27 and GPC-3 were highly expressed in the PHC tissues ,the differ-ence had statistical significance compared with their expression levels in the liver cirrhosis tissues ,liver benign neoplasm tissues and hepatitis tissues(P<0 .05) .The expression of HSP-27 in the PHC tissues was correlated with the tumor pathological grade and the TNM stage ,while the expression of GPC-3 was not correlated with the tumor pathological grade and the TNM stage .Conclusion The high expression of HSP-27 and GPC-3 in the PHC tissue is closely related with the tumorigenesis ,progress ,metastasis of PHC ,which may become new pathological diagnosis markers of PHC .

High-mobility group box 1 ( HMGB1 ) is a conserva-tive nuclear protein and plays an essential role in maintaining nu-cleosome stability, DNA recombination, replication, repair and transcription. It can be passively released by necrotic cells or ac-tively secreted into extracellular under appropriate stimulus. Re-cent studies show that the activation of HMGB1 signaling is closely related to the progress of lung diseases including lung in-jury, pulmonary fibrosis and lung cancer, while blocking HMGB1 signaling inhibits the pathological process, indicating the therapeutic potential of HMGB1 inhibition in treating these diseases. This review summarizes the role and mechanisms of HMGB1 in such diseases, in order to provide novel evidence for the diagnosis and treatment.

A cerebral arteriovenous malformation is a congenital disorder characterised by an abnormal connection between the arteries and the veins in the brain. It causes intracranial bleeding, seizures, severe headache, and progressive neurological deficits. The therapeutic strategies were usually established on the basis of clinical experiences due to lack of ideal models of arteriovenous malformation in the past .In order to further increase the success rate of surgery and decrease complications, this article reviews the advances in establishment and application of animal models of cerebral arteriovenous malformation in recent years.

Tumor surface antigen human epidermal growth factor receptor 2 (Her2) is a type I receptor tyrosine kinase, which belongs to human epidermal growth factor receptor family. Her2-overexpression is associated with tumorigenesis and metastasis. Due to significant clinical effects, Her2-targeted cancer therapy especially therapeutic antibody has become the hot spot in the field of cancer treatment. Anti-Her2 antibody drugs include monoclonal antibodies, antibody-drug conjugates, bispecific antibodies and emerging "two in one" antibody. Based on structure and function of Her2, this review focuses on recent advances in active mechanisms and clinical researches of these antibodies.
Antibodies, Bispecific ; therapeutic use ; Antibodies, Monoclonal ; therapeutic use ; Humans ; Immunoconjugates ; therapeutic use ; Neoplasms ; drug therapy ; Receptor, ErbB-2 ; immunology

Objective To study efficiency and safety of fondaparinux and Enoxaparin in treatment of Chinese patients with acute coronary syndrome (ACS) having undergone percutaneous coronary intervention (PCI). Methods One thousand and sixty ACS patients (945 with unstable angina, 115 with AMI) having undergone PCI in Henan provincial hospital from July 2011 to July 2013 were randomized into two groups treated with fondaparinux or enoxaparin respectively. Apart from treatment with oral aspirin and clopidogrel, those in the former group were treated with fondaparinux (2.5 mg IH QD) and the latter with enoxaparin (60 mg IH Q12H) subcutaneously for 2 days before operation, both suspended for 12 h before the operation. All of the patients were given heparin (60 IU/kg) during the operation. After the operation, the therapies with fondaparinux (2.5 mg IH QD) and enoxaparin (60 mg IH Q12H) were resumed subcutaneously for 3 days. Perioperative observation and follow-ups were made in terms of hemorrhage, thrombosis and major adverse cardiac events (MACE) in the patients during the hospitalization period, 2 and 4 weeks after operation. Results Fondaparinux and enoxaparin are both effective on anticoagulation for the patients after PCI. There was no significant difference about the incidence of MACE between the two groups (P > 0.05). But, fondaparinux group had lower incidence of hemorrhage than enoxaparin group (P < 0.05). Conclusion Fondaparinux and enoxaparin both have good anticoagulant activity in Chinese patients with ACS undergoing PCI, but fondaparinux may lower the risk of hemorrhage compared to enoxaparin.

Cardiomyopathy, Hypertrophic ; complications ; Fatal Outcome ; Heart Septal Defects, Atrial ; complications ; Humans ; Infant

Objective To establish a HPLC method for the determination of kaempferol-7-O-?-D-glucopyranoside in Hosta ventricosa stearn.Methods HPLC ana1ysis was carried out on a Phenomenex Luna C18(250 mm?4.6 mm,5 ?m) column,gradient elution with the mobile phase of 0.5 % phosphate acid in water-methanol.The detective wavelength was set at 364 nm.Results calibration curve was linear within the range of 0.113 ～ 2.260 ?g for kaempferol-7-O-?-D-glucopyranoside,coefficient correlation being 1.The average recovery was 101.1 %(RSD= 2.58 %,n=6).Conclusion The content of kaempferol-7-O-?-D-glucopyranoside in Hosta ventricosa stearn is 0.2 mg/g(0.02 %) on average.This method is simple,accurate and practical for the determination of kaempferol-7O-?-D-glucopyranoside.

Objective To compare clinical effects between percutaneous and open reduction by using tension band wiring for the treatment of transverse patella fractures. Methods A prospective study was carried out. A series of 62 cases of transverse patella fracture from 1997 to 2003 were divided into two groups: the Percutaneous Group (n=27) and the Open Group (n=35). The Percutaneous Group received percutaneous reduction with tension band fixation, including 23 cases of internal fixation by Kirschner-wire techniques and 4 cases of fixation through cannulated cancellous bone screws. The Open Group received open reduction with Kirschner wiring tension band fixation. The time to bone union, the reduction condition, the movement range and the function of the knee were compared between the two groups. Results All the cases were followed for 6~48 months. The bone union was achieved in both of groups. The rate of “good” or “excellent” knee functions was 88.9% in the Percutaneous Group (24/27) and 88.6% in the Open Group (31/35), respectively, without significant difference (?2=0.000,P=1.000). The time to bone union was earlier in the Percutaneous Group than in the Open Group (?2=6.581,P=0.037). Conclusions Percutaneous reduction with tension band fixation can offer good anatomic reduction and enough fixation strength to meet the requirements for bone union and function recovery in the treatment of transverse patella fractures, with minimal invasion, quick union and excellent clinical outcomes.

Tumor surface antigen human epidermal growth factor receptor 2 (Her2) is a type I receptor tyrosine kinase, which belongs to human epidermal growth factor receptor family. Her2-overexpression is associated with tumorigenesis and metastasis. Due to significant clinical effects, Her2-targeted cancer therapy especially therapeutic antibody has become the hot spot in the field of cancer treatment. Anti-Her2 antibody drugs include monoclonal antibodies, antibody-drug conjugates, bispecific antibodies and emerging "two in one" antibody. Based on structure and function of Her2, this review focuses on recent advances in active mechanisms and clinical researches of these antibodies.